Comparative Pharmacology
Head-to-head clinical analysis: APADAZ versus NUCYNTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APADAZ versus NUCYNTA.
APADAZ vs NUCYNTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APADAZ is a combination of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Hydrocodone acts as a full mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen's mechanism involves inhibition of cyclooxygenase (COX) enzymes, particularly in the CNS, and modulation of serotonergic pathways, contributing to analgesia and antipyresis.
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
Each tablet contains benzhydrocodone 4.08 mg (hydrocodone 3.33 mg) and acetaminophen 325 mg. One to 2 tablets every 4 to 6 hours as needed for pain; maximum 12 tablets per 24 hours.
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours for benzhydrocodone; context: immediate-release, dosing every 4-6 hours.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals.
Renal: ~90% as conjugates, ~10% unchanged; fecal: minimal; enterohepatic recirculation occurs.
Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces).
Category C
Category C
Opioid Analgesic
Opioid Analgesic